ASH 2018: Recommendations From Dr. Cristhiam Rojas Hernandez
Dr. Cristhiam Rojas Hernandez, an associate editor of PracticeUpdate Benign Hematology, and an assistant professor of hematology at the MD Anderson Cancer Center in Houston, recommends the following papers to be presented at the American Society of Hematology (ASH) 60th Annual Meeting and Exposition to be held December 1–4, 2018, in San Diego.
Sunday, December 2, 2018; 2:00 PM–4:00 PM
Plenary Scientific Session: Biological Processes
1 The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. P Fenaux, U Platzbecker, GJ Mufti, et al
2 Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice. J Xavier-Ferrucio, X Li, V Scanlon, et al
3 Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa. L Tshilolo, G Tomlinson, TN Williams, et al
4 Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. C Pecquet, T Balligand, I Chachoua, et al
5 Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets. I Iacobucci, E Varotto, C Qu, et al
6 Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. JA Woyach, AS Ruppert, NA Heerema, et al
Saturday, December 1, 2018; 12:00 PM–1:30 PM
Oral and Poster Abstracts: Disorders of Platelet Number or Function: New Insights into the Pathology of ITP
127 Expression Differences Distinguish Pediatric Acute and Chronic ITP Using RNA Sequencing. T Kim, H Kim, P Sumazin, et al
128 Immature Platelet Fraction: A Useful Marker for Identifying the Cause of Thrombocytopenia and Predicting Platelet Recovery. YK Lee, K Jeon, M Kim, et al
129 Fcγ Receptors I and III on Splenic Macrophages Mediate Gpiib/Iiia Autoantibody-Dependent Phagocytosis of Platelets in Human Immune Thrombocytopenia. PAA Norris, GB Segel, UJ Sachs, et al
130 Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia. S Ibrahimi, J George, PM Gaffney, et al
131 Somatic Mutations in CD8+ T Cells in Patients with Chronic Immune Thrombocytopenia Are Associated with Increased Clonality and Cytotoxic Phenotype of CD8+ T Cells. H Rajala, P Savola, S Lundgren, et al
132 Atorvastatin Restored the CD4+ T Cell Homeostasis By Regulating the Axis of Effector T Cells and Regulatory T Cells in Immune Thrombocytopenia. P Xu, Y Zhao, M Hou, et al
Sunday, December 2, 2018; 4:30 PM–6:00 PM
Oral and Poster Abstracts: Antithrombotic Therapy: Management of Challenging Patients and Scenarios
421 Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial. RD McBane, WE Wysokinski, J Le-Rademacher, et al
422 Noac Therapy Is Also Effective and Safe in Patients Older Than 80 Years – Results of the Prospective Dresden Noac Registry (NCT01588119). J Beyer-Westendorf, L Tittl, C Naue, S Marten
423 Efficacy and Safety of Direct Oral Factor Xa Inhibitors in 795 Morbidly Obese Patients. M Kushnir, Y Choi, R Eisenberg, et al
424 Double Blind Randomized Control Trial of Postoperative Low Molecular Weight Heparin Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2). MJ Kovacs, M Rodger, PS Wells, et al
425 Heparin Vs Direct Thrombin Inhibitors in Patients with Previous HIT Undergoing Cardiothoracic Surgery: The Cleveland Clinic Experience. DS Carlson, KR McCrae, S Chaturvedi
426 Evaluation of Definitions for Oral Anticoagulant-Associated Major Bleeding: A Population-Based Cohort Study. Y Xu, T Gomes, PS Wells, et al
Monday, December 3, 2018; 6:15 PM–7:45 PM
Oral and Poster Abstracts: Antithrombotic Therapy: New Drugs and Technology
985 Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). JI Zwicker, BL Schlechter, JD Stopa, et al
990 A Novel Anti-Glycoprotein (GP) Iba-Targeting Chimeric Fibrinolytic Agent Demonstrates In Vivo Efficacy Against Human Platelet-Enriched Thrombi in Mice. R Lyde, H Ahn, V Hayes, et al
987 Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting Time. B Laulicht, S Bakhru, S Steiner, et al
988 Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study. A Opneja, D Maji, P Mohseni, et al
989 Antisense Oligonucleotide Targeting of Thrombopoietin Synthesis Reduces Platelet Count within the Hemostatic Range and Slows Progression of De Novo Mammary Carcinogenesis in the Mmtv-Pymt Mouse. T Shirai, A Revenko, J Tibbits, et al
986 Concomitant Use of Diosmin/Hesperidin and Oral Rivaroxaban Increases Deep Vein Recanalization and Reduces the Incidence of Post-Thrombotic Syndrome in Patients with Proximal Deep Vein Thrombosis. K Lobastov, I Schastlivtsev, V Barinov, et al
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles: